Clinical Trial Update: Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the combination of ivosidenib with mFOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Ivosidenib (ivosidenib)
• mFOLFIRINOX (modified FOLFIRINOX)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING